# EPO

## Overview
The EPO gene encodes erythropoietin, a glycoprotein hormone that plays a pivotal role in the regulation of erythropoiesis, the process of red blood cell production. Erythropoietin is primarily synthesized in the kidneys and acts by binding to the erythropoietin receptor (EPOR) on erythroid progenitor cells in the bone marrow, thereby activating signaling pathways that promote cell survival, proliferation, and differentiation (Bhoopalan2020Erythropoietin; Jelkmann2013Physiology). As a member of the helical cytokine family, erythropoietin is characterized by a four-helix bundle structure, which is essential for its biological activity (Cheetham1998NMR). Beyond its hematopoietic function, erythropoietin has been implicated in tissue protection across various organs, including the heart and brain, through mechanisms that are independent of erythropoiesis (Tsiftsoglou2021Erythropoietin). The gene's expression is tightly regulated by oxygen levels, with hypoxia-inducible factors playing a crucial role in its transcriptional activation (Hu1997In). Mutations in the EPO gene can lead to disorders such as erythrocytosis and anemia, underscoring its clinical significance (Zmajkovic2018A; Bhoopalan2020Erythropoietin).

## Structure
The human erythropoietin (EPO) protein is a glycoprotein hormone with a primary structure consisting of 166 amino acid residues and a calculated molecular weight of 18,398 for the protein moiety (Lai1986Structural). The protein's secondary structure is predominantly alpha-helical, with approximately 50% alpha-helix content as determined by circular dichroism spectroscopy (Lai1986Structural). The tertiary structure of EPO is stabilized by two disulfide bonds between cysteine residues at positions 7 and 161, and 29 and 33, which are crucial for its stability (Lai1986Structural). EPO's structure includes a four-helix bundle, a common motif in helical cytokines, with unique features such as the AB crossover loop passing behind the D helix and antiparallel β-strands in its long crossover loops (Cheetham1998NMR).

EPO undergoes significant post-translational modifications, including glycosylation, which is essential for its biological activity. The protein has three N-linked glycosylation sites at positions 24, 38, and 83, and a potential O-linked glycosylation site at serine 126 (Sasaki1987Carbohydrate; Lai1986Structural). These glycosylations contribute to the protein's stability and bioactivity, although they are not required for receptor binding (Cheetham1998NMR).

## Function
Erythropoietin (EPO) is a glycoprotein hormone primarily produced by the kidneys in response to hypoxia, playing a crucial role in erythropoiesis, the process of red blood cell (RBC) production. EPO functions by binding to the erythropoietin receptor (EPOR) on erythroid progenitor cells in the bone marrow, particularly the colony-forming units-erythroid (CFU-Es) and burst-forming unit-erythroid (BFU-Es). This binding activates several intracellular signaling pathways, including the Janus kinase 2 (JAK2) and signal transducer and activator of transcription 5 (STAT5) pathways, which promote cell survival, proliferation, and differentiation (Bhoopalan2020Erythropoietin; Jelkmann2013Physiology).

EPO's interaction with EPOR also involves the activation of the phosphatidylinositol-3 kinase (PI3K)/AKT and mitogen-activated protein kinase (MAPK) pathways, which further enhance the survival and maturation of erythroid progenitors into mature RBCs (Chateauvieux2011Erythropoietin). This process is essential for maintaining adequate oxygen delivery to tissues, as RBCs are responsible for transporting oxygen throughout the body (Cantarelli2019Erythropoietin).

Beyond erythropoiesis, EPO has been shown to exert tissue-protective effects in various organs, including the heart, brain, and kidneys, by interacting with a heterodimeric receptor complex that does not mediate erythropoiesis but activates similar protective signaling pathways (Tsiftsoglou2021Erythropoietin).

## Clinical Significance
Mutations in the EPO gene can lead to various clinical conditions, primarily affecting red blood cell production. A notable gain-of-function mutation, c.32delG, causes autosomal dominant erythrocytosis by introducing a frameshift in the EPO mRNA, resulting in excessive erythropoietin production from a normally non-coding mRNA. This mutation has been identified in familial erythrocytosis, where affected individuals exhibit elevated hemoglobin levels and symptoms such as headache and dizziness (Zmajkovic2018A; Bhoopalan2020Erythropoietin).

Another mutation, R150Q, is associated with erythroid hypoplasia and severe anemia. This mutation impairs the binding of erythropoietin to its receptor, leading to ineffective erythropoiesis. Patients with this mutation may require regular blood transfusions, although treatment with recombinant erythropoietin has shown significant improvement in hemoglobin levels (Ejaz2021LongTerm; Bhoopalan2020Erythropoietin).

Alterations in the PHD-HIF-EPO regulatory pathway can also result in erythrocytosis or anemia. For instance, mutations that stabilize HIF-2α or affect PHD2 and VHL can lead to erythrocytosis by disrupting the oxygen-sensitive feedback loop that regulates EPO production (Bhoopalan2020Erythropoietin). These genetic variations highlight the complex mechanisms by which EPO gene mutations and regulatory pathway alterations can impact red blood cell production and lead to clinical disorders.

## Interactions
Erythropoietin (EPO) is known for its interactions with various proteins and nucleic acids, which are crucial for its diverse biological functions. EPO interacts with specific S100 proteins, such as S100A2, S100A6, and S100P, through its moderately disordered regions. These interactions are conformation-dependent and are facilitated by the structural flexibility of EPO, particularly in its N-terminal tail and a specific region (140-157) (Kazakov2022Erythropoietin). The interactions with S100 proteins are characterized by high affinity, with equilibrium dissociation constants ranging from 81 nM to 0.5 µM, and are influenced by the Ca2+-induced exposure of hydrophobic residues in S100 proteins (Kazakov2022Erythropoietin).

EPO also engages in DNA-protein interactions, particularly involving its enhancer region. The EPO gene enhancer contains binding sites for hypoxia-inducible factor 1 (HIF-1) and DR-2 binding proteins, which are essential for transcriptional activation under hypoxic conditions. These interactions are crucial for the regulation of EPO expression in response to oxygen levels (Hu1997In).

Additionally, EPO RNA interacts with erythropoietin RNA binding protein (ERBP) in association with heat shock protein 70 (hsp70). This interaction is important for the stability and function of EPO mRNA, particularly under hypoxic conditions (Scandurro1997Interaction).


## References


[1. (Chateauvieux2011Erythropoietin) S. Chateauvieux, C. Grigorakaki, F. Morceau, M. Dicato, and M. Diederich. Erythropoietin, erythropoiesis and beyond. Biochemical Pharmacology, 82(10):1291–1303, November 2011. URL: http://dx.doi.org/10.1016/j.bcp.2011.06.045, doi:10.1016/j.bcp.2011.06.045. This article has 130 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.bcp.2011.06.045)

[2. (Ejaz2021LongTerm) Ayesha Ejaz, Alper Ozcan, Ekrem Unal, Musa Karakukcu, and Vijay G. Sankaran. Long-term patient-customized therapy for a pathogenic epo mutation. Med, 2(1):33-37.e1, January 2021. URL: http://dx.doi.org/10.1016/j.medj.2020.10.001, doi:10.1016/j.medj.2020.10.001. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.medj.2020.10.001)

[3. (Hu1997In) Bei Hu, Elizabeth Wright, Laura Campbell, and K. L. Blanchard. In vivo analysis of dna-protein interactions on the human erythropoietin enhancer. Molecular and Cellular Biology, 17(2):851–856, February 1997. URL: http://dx.doi.org/10.1128/MCB.17.2.851, doi:10.1128/mcb.17.2.851. This article has 27 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/MCB.17.2.851)

[4. (Sasaki1987Carbohydrate) H Sasaki, B Bothner, A Dell, and M Fukuda. Carbohydrate structure of erythropoietin expressed in chinese hamster ovary cells by a human erythropoietin cdna. Journal of Biological Chemistry, 262(25):12059–12076, September 1987. URL: http://dx.doi.org/10.1016/s0021-9258(18)45317-3, doi:10.1016/s0021-9258(18)45317-3. This article has 371 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/s0021-9258(18)45317-3)

[5. (Scandurro1997Interaction) Aline B. Scandurro, Isaac J. Rondon, Russell B. Wilson, Scott A. Tenenbaum, Robert F. Garry, and Barbara S. Beckman. Interaction of erythropoietin rna binding protein with erythropoietin rna requires an association with heat shock protein 70. Kidney International, 51(2):579–584, February 1997. URL: http://dx.doi.org/10.1038/ki.1997.83, doi:10.1038/ki.1997.83. This article has 16 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/ki.1997.83)

[6. (Bhoopalan2020Erythropoietin) Senthil Velan Bhoopalan, Lily Jun-shen Huang, and Mitchell J. Weiss. Erythropoietin regulation of red blood cell production: from bench to bedside and back. F1000Research, 9:1153, September 2020. URL: http://dx.doi.org/10.12688/f1000research.26648.1, doi:10.12688/f1000research.26648.1. This article has 51 citations and is from a peer-reviewed journal.](https://doi.org/10.12688/f1000research.26648.1)

[7. (Tsiftsoglou2021Erythropoietin) Asterios S. Tsiftsoglou. Erythropoietin (epo) as a key regulator of erythropoiesis, bone remodeling and endothelial transdifferentiation of multipotent mesenchymal stem cells (mscs): implications in regenerative medicine. Cells, 10(8):2140, August 2021. URL: http://dx.doi.org/10.3390/cells10082140, doi:10.3390/cells10082140. This article has 56 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cells10082140)

[8. (Cheetham1998NMR) Janet C. Cheetham, Duncan M. Smith, Kenneth H. Aoki, Janice L. Stevenson, Thomas J. Hoeffel, Rashid S. Syed, Joan Egrie, and Timothy S. Harvey. Nmr structure of human erythropoietin and a comparison with its receptor bound conformation. Nature Structural Biology, 5(10):861–866, October 1998. URL: http://dx.doi.org/10.1038/2302, doi:10.1038/2302. This article has 142 citations.](https://doi.org/10.1038/2302)

[9. (Kazakov2022Erythropoietin) Alexey S. Kazakov, Evgenia I. Deryusheva, Andrey S. Sokolov, Maria E. Permyakova, Ekaterina A. Litus, Victoria A. Rastrygina, Vladimir N. Uversky, Eugene A. Permyakov, and Sergei E. Permyakov. Erythropoietin interacts with specific s100 proteins. Biomolecules, 12(1):120, January 2022. URL: http://dx.doi.org/10.3390/biom12010120, doi:10.3390/biom12010120. This article has 9 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/biom12010120)

[10. (Zmajkovic2018A) Jakub Zmajkovic, Pontus Lundberg, Ronny Nienhold, Maria L. Torgersen, Anders Sundan, Anders Waage, and Radek C. Skoda. A gain-of-function mutation inepoin familial erythrocytosis. New England Journal of Medicine, 378(10):924–930, March 2018. URL: http://dx.doi.org/10.1056/NEJMoa1709064, doi:10.1056/nejmoa1709064. This article has 60 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1056/NEJMoa1709064)

[11. (Lai1986Structural) P H Lai, R Everett, F F Wang, T Arakawa, and E Goldwasser. Structural characterization of human erythropoietin. Journal of Biological Chemistry, 261(7):3116–3121, March 1986. URL: http://dx.doi.org/10.1016/s0021-9258(17)35756-3, doi:10.1016/s0021-9258(17)35756-3. This article has 296 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/s0021-9258(17)35756-3)

[12. (Cantarelli2019Erythropoietin) Chiara Cantarelli, Andrea Angeletti, and Paolo Cravedi. Erythropoietin, a multifaceted protein with innate and adaptive immune modulatory activity. American Journal of Transplantation, 19(9):2407–2414, September 2019. URL: http://dx.doi.org/10.1111/ajt.15369, doi:10.1111/ajt.15369. This article has 45 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1111/ajt.15369)

[13. (Jelkmann2013Physiology) Wolfgang Jelkmann. Physiology and pharmacology of erythropoietin. Transfusion Medicine and Hemotherapy, 40(5):302–309, 2013. URL: http://dx.doi.org/10.1159/000356193, doi:10.1159/000356193. This article has 179 citations and is from a peer-reviewed journal.](https://doi.org/10.1159/000356193)